Showing 51-60 of 3476 results for "".
- Revealed: Why Skin Feels “Tight” After Using a Facial Cleanserhttps://practicaldermatology.com/news/revealed-why-skin-feels-tight-after-using-a-facial-cleanser/2462023/Some cleansers make the skin feel “tight” and some moisturizers make the skin feel “soft,” but exactly why this occurs hasn't been fully understood. To find out, Reinhold H. Dauskardt, the Ruth G. and William K. Bowes Professor in Stanford’s
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Cardamonin Shows Antifibrotic Activity in Human Keloid Fibroblasts: Studyhttps://practicaldermatology.com/news/cardamonin-shows-antifibrotic-activity-in-human-keloid-fibroblasts-study/2488327/Cardamonin demonstrated antifibrotic activity in human keloid fibroblasts by suppressing transforming growth factor β1 (TGF-β1)/Smad signaling, according to new in vitro research in the Journal of Drugs in Dermatology.
- Study Finds Racial Variation in Keloid Treatmenthttps://practicaldermatology.com/news/study-finds-racial-variation-in-keloid-treatment/2488178/An electronic health record analysis found differences in how keloids are treated across racial groups. In a Letter to the Editor published in the Journal of Drugs in Dermatology, investigators evaluated treatment patterns among adults with keloids using the TriNetX Research Netwo
- Merz Aesthetics Announces FDA Clearance of Ultherapy PRIME for Knee Skin Laxityhttps://practicaldermatology.com/news/merz-aesthetics-announces-fda-clearance-of-ultherapy-prime-for-knee-skin-laxity/2488072/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME (Merz Aesthetics) to improve the appearance of skin laxity on the knees, according to an announcement from the company. Merz Aesthetics said the clearance makes Ultherapy PRIME the first energy-based aesthetic device wit
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://practicaldermatology.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Oral STAT6 Degrader KT-621 Shows Early Promise in Atopic Dermatitishttps://practicaldermatology.com/news/oral-stat6-degrader-kt-621-shows-early-promise-in-atopic-dermatitis/2486423/A first-in-class oral STAT6 degrader, KT-621, demonstrated early clinical activity, robust biomarker suppression, and a favorable safety profile in adults with moderate-to-severe atopic dermatitis (AD), according to Phase 1b data presented by Mahta Mortezavi, MD, at the American Academy of Dermat
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Arcutis Ends Kowa Promotional Partnership, Assumes Control of ZORYVE Promotionshttps://practicaldermatology.com/news/arcutis-ends-kowa-deal-assumes-full-control-of-zoryve-outreach/2485454/Arcutis Biotherapeutics has terminated its co-promotion agreement with Kowa Pharmaceuticals America, Inc. for ZORYVE® (roflumilast), effective January 23, 2026, according to a press relase from the company. Under the prior arran